EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Petlife Pharmaceuticals's Enterprise Value is $0.04 Mil.
Petlife Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2018 was $-0.26 Mil. Therefore, Petlife Pharmaceuticals's EV-to-FCF for today is -0.15.
The historical rank and industry rank for Petlife Pharmaceuticals's EV-to-FCF or its related term are showing as below:
PTLF'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.15 Med: 0 Max: 0
Current: -0.15
PTLF's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 20.16
vs PTLF: -0.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Petlife Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Petlife Pharmaceuticals's share price for today is $0.0002.
Petlife Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.057.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Petlife Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petlife Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petlife Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Petlife Pharmaceuticals's EV-to-FCF falls into.
Petlife Pharmaceuticals's current Enterprise Value is $0.04 Mil.
Petlife Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Feb. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petlife Pharmaceuticals (PTLF) has a EV-to-FCF of -0.15 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Petlife Pharmaceuticals and its competitors.
Is Petlife Pharmaceuticals' EV-to-FCF too high?
Petlife Pharmaceuticals' current EV-to-FCF is -0.15.
How does Petlife Pharmaceuticals' EV-to-FCF compare to PCYN and YBAO?
Petlife Pharmaceuticals' EV-to-FCF of -0.15 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-FCF is 20.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Petlife Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petlife Pharmaceuticals's current EV-to-FCF is -0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petlife Pharmaceuticals stock overvalued right now?
Petlife Pharmaceuticals (PTLF) has a current EV-to-FCF of -0.15. The current EV-to-FCF is -0.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Petlife Pharmaceuticals (PTLF), the current EV-to-FCF is -0.15 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTLF has been successfully added to your 